Peyronie’s Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities

References

• Carriere SP, Pytell JD, Saltzman AF, Fuselier HA. Peyronie’s Disease: a Historical Perspective. Am J Mens Health. 2014;8(5):434–439. doi:10.1177/1557988314520951
   Web of Science ®Google Scholar
• Al-Thakafi S, Al-Hathal N. Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol. 2016;5(3):280–289. doi:10.21037/tau.2016.04.05
   Web of Science ®Google Scholar
• Loftus CJ, Rajanahally S, Holt SK, Raheem OA, Ostrowski KA, Walsh TJ. Treatment trends and cost associated with Peyronie’s disease. Sex Med. 2020;8(4):673–678. doi:10.1016/j.esxm.2020.08.003
   Web of Science ®Google Scholar
• Miner MM, Seftel AD. Peyronie’s disease: epidemiology, diagnosis, and management. Curr Med Res Opin. 2014;30(1):113–120. doi:10.1185/03007995.2013.842544
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175(6):2115–8; discussion 2118. doi:10.1016/s0022-5347(06)00270-9
   PubMed Web of Science ®Google Scholar
• Di Maida F, Cito G, Lambertini L, et al. The natural history of Peyronie’s disease. World J Mens Health. 2021;39(3):399–405. doi:10.5534/wjmh.200065
   Google Scholar
• De Rose AF, Mantica G, Bocca B, Szpytko A, Van der Merwe A, Terrone C. Supporting the role of penile trauma and micro-trauma in the etiology of Peyronie’s disease. Prospective observational study using the electronic microscope to examine two types of plaques. Aging Male. 2020;23(5):740–745. doi:10.1080/13685538.2019.1586870
   PubMed Web of Science ®Google Scholar
• Casabé A, Bechara A, Cheliz G, De Bonis W, Rey H. Risk factors of Peyronie’s disease. What does our clinical experience show? J Sex Med. 2011;8(2):518–523. doi:10.1111/j.1743-6109.2010.02072.x
   Web of Science ®Google Scholar
• Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie’s disease: a case-control study. BJU Int. 2006;97(3):570–574. doi:10.1111/j.1464-410X.2006.05969.x
   PubMed Web of Science ®Google Scholar
• Demling RH. The role of anabolic hormones for wound healing in catabolic states. J Burns Wounds. 2005;4:e2.
   PubMedGoogle Scholar
• Can O, Özbir S, Atalay HA, Çakır SS, Culha MG, Canat HL. The relationship between testosterone levels and Peyronie’s disease. Andrologia. 2020;52(9):e13727. doi:10.1111/and.13727
   Web of Science ®Google Scholar
• Lue TF. Peyronie’s disease: an anatomically-based hypothesis and beyond. Int J Impot Res. 2002;14(5):411–413. doi:10.1038/sj.ijir.3900876
   PubMed Web of Science ®Google Scholar
• El-Sakka AI, Salabas E, Dinçer M, Kadioglu A. The pathophysiology of Peyronie’s disease. Arab J Urol. 2013;11(3):272–277. doi:10.1016/j.aju.2013.06.006
   PubMedGoogle Scholar
• Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int. 2003;91(9):830–838. doi:10.1046/j.1464-410x.2003.04224.x
   PubMed Web of Science ®Google Scholar
• Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie’s disease. Int J Impot Res. 2002;14(5):353–360. doi:10.1038/sj.ijir.3900880
   PubMed Web of Science ®Google Scholar
• Watanabe MS, Theodoro TR, Coelho NL, et al. Extracellular matrix alterations in the Peyronie’s disease. J Adv Res. 2017;8(4):455–461. doi:10.1016/j.jare.2017.06.004
   Web of Science ®Google Scholar
• Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by Interleukin-1β and transforming growth Factor-β in Peyronie’s plaque fibroblasts. J Urol. 2008;179(6):2447–2455. doi:10.1016/j.juro.2008.01.093
   PubMed Web of Science ®Google Scholar
• Paulis G, Romano G, Paulis L, Barletta D. Recent pathophysiological aspects of Peyronie’s disease: role of free radicals, rationale, and therapeutic implications for antioxidant Treatment—Literature Review. Adv Urol. 2017;2017:4653512. doi:10.1155/2017/4653512
   Google Scholar
• Zhang F, Qin F, Yuan J. Molecular mechanisms and current pharmacotherapy of Peyronie’s disease: a review. Front Pharmacol. 2021;12:643641. doi:10.3389/fphar.2021.643641
   Web of Science ®Google Scholar
• Chung E, De Young L, Solomon M, Brock GB. Peyronie’s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie’s disease in a cell-culture strain system. J Sex Med. 2013;10(5):1259–1267. doi:10.1111/jsm.12082
   PubMed Web of Science ®Google Scholar
• Hatfield BS, King CR, Udager AM, et al. Peyronie disease: a clinicopathologic study of 71 cases with emphasis on histopathologic patterns and prevalent metaplastic ossification. Hum Pathol. 2020;104:9–17. doi:10.1016/j.humpath.2020.07.013
   Web of Science ®Google Scholar
• Patel DP, Christensen MB, Hotaling JM, Pastuszak AW. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol. 2020;38(2):253–261. doi:10.1007/s00345-019-02815-6
   PubMed Web of Science ®Google Scholar
• Castiglione F, Hedlund P, Weyne E, et al. Intratunical injection of human adipose tissue–derived stem cells restores collagen III/I ratio in a rat model of chronic Peyronie’s disease. Sex Med. 2019;7(1):94–103. doi:10.1016/j.esxm.2018.09.003
   PubMed Web of Science ®Google Scholar
• Ustriyana P, Hennefarth MR, Srirangapatanam S, et al. Mineralized Peyronie’s plaque has a phenotypic resemblance to bone. Acta Biomater. 2022;140:457–466. doi:10.1016/j.actbio.2021.11.025
   Web of Science ®Google Scholar
• Gonzalez-Cadavid NF, Magee TR, Ferrini M, Qian A, Vernet D, Rajfer J. Gene expression in Peyronie’s disease. Int J Impot Res. 2002;14(5):361–374. doi:10.1038/sj.ijir.3900873
   PubMed Web of Science ®Google Scholar
• Rainer QC, Rodriguez AA, Bajic P, Galor A, Ramasamy R, Masterson TA. Implications of calcification in Peyronie’s disease, a review of the literature. Urology. 2021;152:52–59. doi:10.1016/j.urology.2021.01.007
   Web of Science ®Google Scholar
• Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098
   PubMed Web of Science ®Google Scholar
• Bilgutay AN, Pastuszak AW. Peyronie’s disease: a review of etiology, diagnosis, and management. Curr Sex Health Rep. 2015;7(2):117–131. doi:10.1007/s11930-015-0045-y
   Google Scholar
• Alwaal A, Awad M, Boggs N, Kuzbel J, Snoad B. Sexual health inventory for men questionnaire as a screening method for erectile dysfunction in a general urology clinic. Sex Med. 2020;8(4):660–663. doi:10.1016/j.esxm.2020.08.002
   PubMed Web of Science ®Google Scholar
• Bacal V, Rumohr J, Sturm R, Lipshultz LI, Schumacher M, Grober ED. Correlation of degree of penile curvature between patient estimates and objective measures among men with Peyronie’s disease. J Sex Med. 2009;6(3):862–865. doi:10.1111/j.1743-6109.2008.01158.x
   PubMed Web of Science ®Google Scholar
• Wang CX, Flick TR, Patel AH, Sanchez F, Sherman WF. Patients with Dupuytren’s contracture, Ledderhose disease, and Peyronie’s Disease are at higher risk of arthrofibrosis following total knee arthroplasty. Knee. 2021;29:190–200. doi:10.1016/j.knee.2021.02.009
   Web of Science ®Google Scholar
• Chen JY, Hockenberry MS, Lipshultz LI. Objective assessments of Peyronie’s disease. Sex Med Rev. 2018;6(3):438–445. doi:10.1016/j.sxmr.2017.12.006
   Web of Science ®Google Scholar
• Pawłowska E, Bianek-Bodzak A. Imaging modalities and clinical assesment in men affected with Peyronie’s disease. Pol J Radiol. 2011;76(3):33–37.
   Google Scholar
• Hoyland K, Vasdev N, Adshead J. The use of vacuum erection devices in erectile dysfunction after radical prostatectomy. Rev Urol. 2013;15(2):67–71.
   Google Scholar
• Lin H, Wang R. The science of vacuum erectile device in penile rehabilitation after radical prostatectomy. Transl Androl Urol. 2013;2(1):61–66. doi:10.3978/j.issn.2223-4683.2013.01.04
   Google Scholar
• Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468–1473. doi:10.1111/j.1743-6109.2008.00814.x
   PubMed Web of Science ®Google Scholar
• Ziegelmann MJ, Farrell MR, Levine LA. Modern treatment strategies for penile prosthetics in Peyronie’s disease: a contemporary clinical review. Asian J Androl. 2020;22(1):51–59. doi:10.4103/aja.aja_81_19
   Web of Science ®Google Scholar
• MacDonald LP, Armstrong ML, Lehmann KJ, Acker MR, Langille GM. Outcome analysis of patients with Peyronie’s disease who elect for vacuum erection device therapy. Can Urol Assoc J. 2020;14(9):E428–e431. doi:10.5489/cuaj.6205
   Web of Science ®Google Scholar
• Raheem AA, Garaffa G, Raheem TA, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178–1180. doi:10.1111/j.1464-410X.2010.09365.x
   PubMed Web of Science ®Google Scholar
• Avant RA, Ziegelmann M, Nehra A, Alom M, Kohler T, Trost L. Penile traction therapy and vacuum erection devices in Peyronie’s disease. Sex Med Rev. 2019;7(2):338–348. doi:10.1016/j.sxmr.2018.02.005
   Web of Science ®Google Scholar
• Haney NM, Kohn TP, Nichols PE, Jg Hellstrom W. The effect of adjunct mechanical traction on penile length in men undergoing primary treatment for Peyronie’s disease: a systematic review and meta-analysis. Urology. 2018;122:110–115. doi:10.1016/j.urology.2018.07.039
   Web of Science ®Google Scholar
• Moncada I, Krishnappa P, Romero J, et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie’s disease: a controlled multicentre study. BJU Int. 2019;123(4):694–702. doi:10.1111/bju.14602
   PubMed Web of Science ®Google Scholar
• Ziegelmann M, Savage J, Toussi A, et al. Outcomes of a novel penile traction device in men with Peyronie’s disease: a randomized, single-blind, controlled trial. J Urol. 2019;202(3):599–610. doi:10.1097/ju.0000000000000245
   PubMed Web of Science ®Google Scholar
• Capoccia E, Ziegelmann M, Emmerson J, Lankford J, Ofori-Marfoh C, Levine L. Long-term patient-reported outcomes in men with Peyronie’s disease undergoing nonsurgical and nonintralesional injection management. Int J Impot Res. 2021;33(1):75–81. doi:10.1038/s41443-020-0231-y
   Web of Science ®Google Scholar
• Bole R, White L, Parikh N, Helo S, Kohler T, Ziegelmann M. A modern review of penile traction monotherapy and combination therapy for the treatment of peyronie’s disease. Int J Impot Res. 2021;33(3):251–258. doi:10.1038/s41443-020-0247-3
   Web of Science ®Google Scholar
• Yang KK, Bennett N. The history of collagenase clostridium histolyticum. Sex Med Rev. 2015;3(4):289–297. doi:10.1002/smrj.54
   Google Scholar
• Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ. Role of collagenase clostridium histolyticum in Peyronie’s disease. Biologics. 2015;9:107–116. doi:10.2147/btt.s65619
   PubMedGoogle Scholar
• Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled Phase 3 studies. J Urol. 2013;190(1):199–207. doi:10.1016/j.juro.2013.01.087
   PubMed Web of Science ®Google Scholar
• Goldstein I, Lipshultz LI, McLane M, et al. Long-term safety and curvature deformity characterization in patients previously treated with collagenase clostridium histolyticum for Peyronie’s disease. J Urol. 2020;203(6):1191–1197. doi:10.1097/ju.0000000000000743
   PubMed Web of Science ®Google Scholar
• Hellstrom WJG, Tue Nguyen HM, Alzweri L, et al. Intralesional collagenase clostridium histolyticum causes meaningful improvement in men with Peyronie’s disease: results of a multi-institutional analysis. J Urol. 2019;201(4):777–782. doi:10.1097/ju.0000000000000032
   PubMed Web of Science ®Google Scholar
• Goldstein I, Knoll LD, Lipshultz LI, Smith T, Kaufman GJ, McMahon CG. Changes in the effects of Peyronie’s disease after treatment with collagenase clostridium histolyticum: male patients and their female partners. Sex Med. 2017;5(2):e124–e130. doi:10.1016/j.esxm.2017.02.001
   PubMed Web of Science ®Google Scholar
• Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195(4 Pt 1):1051–1056. doi:10.1016/j.juro.2015.10.065
   PubMedGoogle Scholar
• Nguyen HMT, DeLay KJ, Diao L, et al. Racial variations in response to intralesional collagenase clostridium histolyticum in men with Peyronie’s disease. Transl Androl Urol. 2017;6(5):888–893. doi:10.21037/tau.2017.07.26
   Web of Science ®Google Scholar
• Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie’s disease using a new modified shortened protocol. BJU Int. 2017;120(5):717–723. doi:10.1111/bju.13932
   PubMed Web of Science ®Google Scholar
• Cocci A, Russo GI, Briganti A, et al. Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie’s disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int. 2018;122(4):680–687. doi:10.1111/bju.14410
   PubMed Web of Science ®Google Scholar
• Capece M, Cocci A, Russo G, et al. Collagenase clostridium histolyticum for the treatment of Peyronie’s disease: a prospective Italian multicentric study. Andrology. 2018;6(4):564–567. doi:10.1111/andr.12497
   PubMed Web of Science ®Google Scholar
• Cao D, Li J, Lu Y, et al. Efficacy and safety of collagenase clostridium histolyticum in the treatment of Peyronie’s disease: an evidence-based analysis. Front Med. 2022;9:780956. doi:10.3389/fmed.2022.780956
   Web of Science ®Google Scholar
• Carson CC, Sadeghi-Nejad H, Tursi JP, et al. Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie’s disease (PD). BJU Int. 2015;116(5):815–822. doi:10.1111/bju.13120
   PubMed Web of Science ®Google Scholar
• Lipshultz LI, Goldstein I, Seftel AD, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie’s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, Phase III studies. BJU Int. 2015;116(4):650–656. doi:10.1111/bju.13096
   PubMed Web of Science ®Google Scholar
• Diao L, Anaissie J, Nguyen HMT, et al. Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie’s disease. Transl Androl Urol. 2017;6(5):894–898. doi:10.21037/tau.2017.07.27
   Web of Science ®Google Scholar
• Yafi FA, Hatzichristodoulou G, Knoedler CJ, Trost LW, Sikka SC, Hellstrom WJ. Comparative analysis of tunical plication vs. intralesional injection therapy for ventral Peyronie’s disease. J Sex Med. 2015;12(12):2492–2498. doi:10.1111/jsm.13072
   Web of Science ®Google Scholar
• Greenberg J, Soubra A, Kim J, et al. Xiaflex® treatment for Peyronie’s disease may improve penile curvature degree with no effect on the loss on penile length in post-marketing analysis. J Sex Med. 2022;19(4):S36–S37.
   Web of Science ®Google Scholar
• Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L. Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie’s Disease. Urology. 2018;119:109–114. doi:10.1016/j.urology.2018.06.003
   PubMed Web of Science ®Google Scholar
• Bajic P, Wiggins AB, Ziegelmann MJ, Levine LA. Characteristics of men with Peyronie’s disease and collagenase clostridium histolyticum treatment failure: predictors of surgical intervention and outcomes. J Sex Med. 2020;17(5):1005–1011. doi:10.1016/j.jsxm.2020.02.002
   Web of Science ®Google Scholar
• Yousif A, Tue Nguyen HM, Shalaby H, Hellstrom W. MP33-17 efficacy and safety of collagenase Clostridium Histolyticum (CCH) treatment in Peyronie’s disease patients with and without calcification. J Urol. 2020;203(Supplement 4):e501–e501.
   Google Scholar
• Heslop D, Helo S, Houlihan M, Bajic P, Kohler T, Ziegelmann M. MP33-09 hourglass deformity portends a lower likelihood of restoring penetration and preventing surgery with collagenase for Peyronie’s disease. J Urol. 2020;203(Supplement 4):e497–e498.
   Google Scholar
• Chung E, Garcia F, Young LD, Solomon M, Brock GB. A comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcome. J Urol. 2013;189(1):380–384. doi:10.1016/j.juro.2012.08.191
   PubMed Web of Science ®Google Scholar
• Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522–1524. doi:10.1016/s0022-5347(17)35291-6
   PubMed Web of Science ®Google Scholar
• Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168(2):621–5; discussion 625–6. doi:10.1016/s0022-5347(05)64691-5
   Web of Science ®Google Scholar
• Favilla V, Russo GI, Zucchi A, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie’s disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5(4):771–775. doi:10.1111/andr.12368
   PubMed Web of Science ®Google Scholar
• Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology. 1998;51(4):620–626. doi:10.1016/s0090-4295(97)00700-0
   PubMed Web of Science ®Google Scholar
• Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467–471. doi:10.1007/s11255-009-9522-4
   PubMed Web of Science ®Google Scholar
• Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972–975. doi:10.1016/j.juro.2006.10.065
   PubMed Web of Science ®Google Scholar
• Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89–94. doi:10.3109/00365599109024539
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–398. doi:10.1016/s0022-5347(06)00517-9
   PubMed Web of Science ®Google Scholar
• Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJ. Outcomes of intralesional interferon-α2B for the treatment of Peyronie disease. J Urol. 2013;190(6):2194–2199. doi:10.1016/j.juro.2013.05.022
   PubMed Web of Science ®Google Scholar
• Stewart CA, Yafi FA, Knoedler M, et al. Intralesional injection of interferon-α2b improves penile curvature in men with Peyronie’s disease independent of plaque location. J Urol. 2015;194(6):1704–1707. doi:10.1016/j.juro.2015.06.096
   PubMed Web of Science ®Google Scholar
• Sokhal AK, Jain NK, Jhanwar A, Singh K, Saini DK. Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie’s disease. Urol Ann. 2018;10(2):154–158. doi:10.4103/ua.ua_65_17
   PubMed Web of Science ®Google Scholar
• Alom M, Meng Y, Nguyen HM, et al. MP33-06 intralesional collagenase clostridium histolyticum achieves greater curvature improvements compared to interferon for Peyronie’s disease. J Urol. 2020;203(Supplement 4):e496.
   Google Scholar
• Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology. 2006;67(5):1038–1042. doi:10.1016/j.urology.2005.11.005
   PubMed Web of Science ®Google Scholar
• Sun J, Gao F, Wang Y, Sun W, Jiang B, Li Z. Extracorporeal shock wave therapy is effective in treating chronic plantar fasciitis: a meta-analysis of RCTs. Medicine. 2017;96(15):e6621. doi:10.1097/md.0000000000006621
   Web of Science ®Google Scholar
• Speed C. A systematic review of shockwave therapies in soft tissue conditions: focusing on the evidence. Br J Sports Med. 2014;48(21):1538–1542. doi:10.1136/bjsports-2012-091961
   PubMed Web of Science ®Google Scholar
• Raheem OA, Natale C, Dick B, et al. Novel treatments of erectile dysfunction: review of the current literature. Sex Med Rev. 2021;9(1):123–132. doi:10.1016/j.sxmr.2020.03.005
   Web of Science ®Google Scholar
• Ortac M, Özmez A, Cilesiz NC, Demirelli E, Kadıoğlu A. The impact of extracorporeal shock wave therapy for the treatment of young patients with vasculogenic mild erectile dysfunction: a prospective randomized single-blind, sham controlled study. Andrology. 2021;9(5):1571–1578. doi:10.1111/andr.13007
   Web of Science ®Google Scholar
• Di Mauro M, Russo GI, Della Camera PA, et al. Extracorporeal shock wave therapy in Peyronie’s disease: clinical efficacy and safety from a single-arm observational study. World J Mens Health. 2019;37(3):339–346. doi:10.5534/wjmh.180100
   PubMedGoogle Scholar
• Bakr AM, El-Sakka AI. Extracorporeal shockwave therapy in Peyronie’s Disease: systematic review and meta-analysis. J Sex Med. 2021;18(10):1705–1714. doi:10.1016/j.jsxm.2021.06.012
   Web of Science ®Google Scholar
• Abdessater M, Akakpo W, Kanbar A, et al. Low-intensity extracorporeal shock wave therapy for Peyronie’s disease: a single-center experience. Asian J Androl. 2022;24(1):45–49. doi:10.4103/aja.aja_40_21
   Web of Science ®Google Scholar
• Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Append Disord. 2018;4(1):18–24. doi:10.1159/000477353
   PubMed Web of Science ®Google Scholar
• Poulios E, Mykoniatis I, Pyrgidis N, et al. Platelet-Rich Plasma (PRP) improves erectile function: a double-blind, randomized, placebo-controlled clinical trial. J Sex Med. 2021;18(5):926–935. doi:10.1016/j.jsxm.2021.03.008
   PubMed Web of Science ®Google Scholar
• Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20). doi:10.3390/ijms21207794
   Web of Science ®Google Scholar
• Notsek M, Boiko M. PO-01-083 Platelet-rich plasma therapy of Peyronie’s disease. J Sex Med. 2019;16(5):S70.
   Web of Science ®Google Scholar
• Matz EL, Pearlman AM, Terlecki RP. Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions. Invest Clin Urol. 2018;59(1):61–65. doi:10.4111/icu.2018.59.1.61
   PubMed Web of Science ®Google Scholar
• Virag R, Sussman H. PS-05-007 Plasma rich platelets and hyaluronic acid improves peyronie’s disease: a case control study of 75 cases. J Sex Med. 2017;14(4):e121.
   Web of Science ®Google Scholar
• Khodamoradi K, Dullea A, Golan R, et al. Platelet Rich Plasma (PRP) growth factor concentration varies in men with erectile dysfunction. J Sex Med. 2022. doi:10.1016/j.jsxm.2022.06.003
   Web of Science ®Google Scholar
• Alkandari MH, Touma N, Carrier S. Platelet-rich plasma injections for erectile dysfunction and Peyronie’s disease: a systematic review of evidence. Sex Med Rev. 2022;10(2):341–352. doi:10.1016/j.sxmr.2020.12.004
   Web of Science ®Google Scholar
• Paulis G, Paulis A, Romano G, Barletta D, Fabiani A. Rationale of combination therapy with antioxidants in medical management of Peyronie’s disease: results of clinical application. Res Rep Urol. 2017;9:129–139. doi:10.2147/rru.s141748
   Google Scholar
• Paulis G, De Giorgio G. Full regression of Peyronie’s disease plaque following combined antioxidant treatment: a three-case report. Antioxidants. 2022;9:1661.
   Google Scholar